CureVac announced initiation of P-I part of P-I/II study to evaluate influenza A (H5N1) pre-pandemic vaccine (up to 5 dose levels vs PBO) in collaboration with GSK
P-I/II study assess safety, reactogenicity and immunogenicity of Influenza A (H5N1) pre-pandemic monovalent vaccine in healthy young (18-64yrs.) & old adults (65-85yrs) in US
The CureVac-GSK collaboration announced in Jul’20 focusses on using CureVac’s mRNA technology to develop infectious disease products
Ref: CureVac | Image: CureVac
Related News:- GSK to Highlight Results from the P-III (EAGLE-1) Study of Gepotidacin for Treating Uncomplicated Urogenital Gonorrhoea (GC) at ESCMID 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
